Literature DB >> 26542740

Toward illness phase-specific pharmacotherapy for schizophrenia.

John H Krystal1, Alan Anticevic2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26542740     DOI： 10.1016/j.biopsych.2015.08.017

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  14 in total

Review 1.  Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

Authors:  Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic
Journal:  Biol Psychiatry       Date:  2017-03-14       Impact factor: 13.382

2.  Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Monica E Calkins; Simon N Vandekar; Guray Erus; Kosha Ruparel; David R Roalf; Kristin A Linn; Mark A Elliott; Tyler M Moore; Hakon Hakonarson; Russell T Shinohara; Christos Davatzikos; Ruben C Gur; Raquel E Gur
Journal:  JAMA Psychiatry       Date:  2016-05-01       Impact factor: 21.596

3.  Ketamine Treatment and Global Brain Connectivity in Major Depression.

Authors:  Chadi G Abdallah; Lynnette A Averill; Katherine A Collins; Paul Geha; Jaclyn Schwartz; Christopher Averill; Kaitlin E DeWilde; Edmund Wong; Alan Anticevic; Cheuk Y Tang; Dan V Iosifescu; Dennis S Charney; James W Murrough
Journal:  Neuropsychopharmacology       Date:  2016-09-08       Impact factor: 7.853

Review 4.  Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.

Authors:  Tobias Bast; Marie Pezze; Stephanie McGarrity
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

Review 5.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

6.  Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.

Authors:  Francisco Reyes-Madrigal; Elisa Guma; Pablo León-Ortiz; Gladys Gómez-Cruz; Ricardo Mora-Durán; Ariel Graff-Guerrero; Lawrence S Kegeles; M Mallar Chakravarty; Camilo de la Fuente-Sandoval
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-11-06       Impact factor: 5.067

Review 7.  Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective.

Authors:  John H Krystal; Alan Anticevic; Genevieve J Yang; George Dragoi; Naomi R Driesen; Xiao-Jing Wang; John D Murray
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

Review 8.  The Role of Serine Racemase in the Pathophysiology of Brain Disorders.

Authors:  Joseph T Coyle; Darrick T Balu
Journal:  Adv Pharmacol       Date:  2017-11-29

9.  Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?

Authors:  Joseph J Taylor; John H Krystal; Deepak C D'Souza; Jason Lee Gerrard; Philip R Corlett
Journal:  Schizophr Res       Date:  2017-09-29       Impact factor: 4.939

10.  Peripubertal mGluR2/3 Agonist Treatment Prevents Hippocampal Dysfunction and Dopamine System Hyperactivity in Adulthood in MAM Model of Schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.